Notably, treatment with lovastatin, a specific inhibitor of the rate-limiting enzyme in cholesterol biosynthesis (HMG-CoA reductase), can reduce RAS farnesylation and activity, and has been previously shown to reverse spatial learning deficits in the Nf131 and Ptpn1110 mouse models for RASopathies. Here, HMGCR is linked to RASopathy.